<DOC>
	<DOCNO>NCT00189345</DOCNO>
	<brief_summary>Patients epithelial ovarian cancer , fallopian tube peritoneal cancer receive surgical cytoreduction platinum/taxane contain chemotherapy significant chance enter complete clinical remission 70 % eventually relapse . Many patient respond additional cytotoxic treatment partial complete response , yet approximately 100 % patient ultimately progress . Novel consolidation strategy follow treatment recurrent disease need immunologic approach attractive option.EpCAM express large number epithelial ovarian cancer , fallopian tube peritoneal cancer tissue . Thus target cancer anti-EpCAM antibody promise innovative therapeutic approach .</brief_summary>
	<brief_title>Randomized , Multicenter , 2-Dose Level . Open-Label , Phase IIa Study With Intraperitoneally Infused Trifunctional Bispecific Antibody Removab ( TM ) ( Anti-EpCAM x Anti-CD3 ) Select Better Dose Level Platinum Refractory Epithelial Ovarian Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>woman 18 year old histologically confirm epithelial ovarian cancer , cancer fallopian tube peritoneum measurable disease sign date informed consent one two prior chemotherapy , last platinum contain platinum refractory disease ECOG performance status 02 acute chronic infection previous treatment mouse monoclonal antibody know suspected hypersensitivity removab inadequate renal function inadequate hepatic function ileus cachectic patient</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Cancer alternative therapy</keyword>
	<keyword>ovarian cancer</keyword>
</DOC>